Availability: BPC-157 is not currently orderable from Rebody. This guide covers the molecule and its research, not a live offer.
The short answer
BPC-157 is a fifteen-amino-acid peptide taken from a protein in gastric juice. Its animal studies measured tendon strength, ligament healing, and gut repair directly, which is why it leads the recovery-peptide conversation instead of sitting at the edge of it.
BPC-157 at a glance
| Fact | Detail |
|---|---|
| Full name | Body Protection Compound 157 |
| Structure | Fifteen amino acids, derived from a human gastric juice protein |
| Strongest research lane | Surgically injured rat tendon and ligament models |
| Endpoints measured | Failure load, elasticity, collagen, vascularity, histology |
| Human data | One three-day intravenous pilot in two previously exposed adults |
| Rebody status | Not orderable |
What peptide BPC-157 is
Peptides are short amino acid chains that carry signals between cells. BPC-157 is a fifteen-amino-acid sequence isolated from a larger protein found in human gastric juice, where the parent compound has a protective role in the digestive tract. Researchers named it Body Protection Compound after that origin.
The reason it drew attention outside the gut is that the same peptide showed repair effects in tissue far from the stomach. Rat studies applied it to tendon, ligament, muscle, and bone injuries and measured what happened to the tissue itself.
How BPC-157 works in the research models
Preclinical work points at several overlapping mechanisms rather than one switch:
- Angiogenesis, meaning the growth of new blood vessels into a healing site, which matters most in tendon and ligament tissue that carries a poor blood supply to begin with
- Upregulation of growth factor receptors, including vascular endothelial growth factor pathways involved in that vessel growth
- Nitric oxide signaling, which affects local blood flow and vascular tone
- Collagen organization at the repair site, measured in tendon and ligament models as fiber density and structure
- Cytoprotection, meaning the cell survives an insult it would otherwise be damaged by, first shown in the gastric models
- Fibroblast migration and outgrowth in cell culture, the step that populates a defect with repair tissue
Each item above comes from animal or cell work. The mechanism story is well developed at that level; it has not been reproduced with human clinical endpoints.
BPC-157 peptide benefits in the studies
The claimed benefits split cleanly by how well each one was measured.
Tendon and ligament repair is the strongest lane. Rat Achilles tendon and medial collateral ligament studies used surgical injuries and then measured functional index, failure load, elasticity, collagen content, vascularity, and histology. These are hard tissue endpoints, not questionnaires, and they are the reason BPC-157 outranks every other recovery peptide on evidence quality.
Gut protection is where the molecule started. The parent compound protects gastric tissue, and rodent models of ulcer and intestinal damage showed a protective effect. This lane has the longest history and the most direct link to the peptide's origin.
Muscle and bone healing show up in the same body of animal work, with defect size and repair quality as the measured outcomes.
Vascular and neural findings exist but sit further out. They come from smaller and more specialized rodent models, and they should be read as research direction rather than an expected result.
Injuries and conditions the research targets
Tendinopathy and chronic tendon pain
Achilles tendinopathy, patellar tendon pain, rotator cuff irritation, and tennis elbow all share a tissue that heals slowly because of limited blood flow. That is the exact problem the angiogenesis and collagen findings speak to, and it is why tendon cases dominate the interest in BPC-157.
Ligament injury
The medial collateral ligament model is one of the two strongest study lines. Ligament injuries follow the same slow-healing pattern as tendon injuries and respond to the same loading logic in rehabilitation.
Muscle strain and overuse injury
Muscle work exists in the animal literature, though the endpoints are less consistent than the tendon studies. Overuse injury in particular depends on training load correction, which no peptide performs.
Digestive inflammation and ulcer models
Gastric and intestinal damage models are the oldest lane. Anyone reading about BPC-157 for gut symptoms is reading about rodent work, and human inflammatory bowel disease has established treatments with human trial evidence behind them.
What the human evidence covers
One published human pilot gave intravenous BPC-157 over three days to two adults who had already been exposed to the peptide, and measured short-term liver and kidney laboratory markers. Those markers did not change.
That study answers a narrow question. It says nothing about a subcutaneous course, nothing about tendon or ligament outcomes, and nothing about safety across a broader population or a longer duration. FDA's review of the substance noted the absence of a human safety and effectiveness record, which is the reason BPC-157 is not sold as an approved drug.
So the honest hierarchy runs like this: strong and specific animal tissue evidence, a well-developed mechanism story, and an open human question. That combination is genuinely interesting. It is not the same thing as a proven treatment, and any page telling you otherwise is selling past the data.
Route, dose, and why the details are not interchangeable
The tendon and ligament findings come from rat models with defined injuries, doses, and delivery. The human pilot used intravenous infusion. Neither of those is the same as a subcutaneous vial on a weekly schedule, and evidence does not transfer across route, species, and dose by assumption.
Oral formats raise a separate question. A peptide taken by mouth faces digestive breakdown, and an oral product needs its own evidence rather than borrowing the injectable literature. Milligram strength, solution concentration, and prescribed dose are three different facts, and a label that blurs them is a reason to slow down.
Safety, side effects, and what needs a clinician
Injection-site reactions belong to the route: pain, bruising, bleeding, irritation, or a lump. Spreading warmth, expanding redness, drainage, red streaking, or fever points at a local infection and needs prompt assessment. Facial swelling, breathing difficulty, or fainting is an emergency regardless of what caused it.
Systemic human safety data is thin, which makes several situations worth a direct conversation before anything starts: pregnancy or breastfeeding, immune conditions, clotting disorders, and any active medication list.
Tested athletes have a separate filter entirely. Check the current prohibited list and your governing body's rules first. A substance does not become permitted because it was prescribed, used out of season, or missing from a standard medication list.
Where BPC-157 sits at Rebody
BPC-157 is not orderable from Rebody today. It sits in the preview set alongside the rest of the recovery lane, and the notification list is the way to hear when that changes.
That status is deliberate. Rebody's live catalog is built around treatments with a clinician-reviewable path and a prescription behind them, and BPC-157 does not currently meet that bar in the United States. When the regulatory picture moves, this page will move with it.
What would change the conclusion
The study that would settle this randomizes people with a defined tendon or ligament injury and a standardized rehabilitation protocol to a specified subcutaneous BPC-157 product or a control, then measures strength, load tolerance, return-to-activity time, adverse events, and durability, while reporting concentration, dose, schedule, and every co-intervention.
Until a trial of that shape exists, progressive loading under a clinician remains the measurable human recovery pathway, and BPC-157 remains the peptide with the closest tissue-level research to it.
Questions people ask about BPC-157
What is BPC-157 used for?
In research, it is used to study tendon, ligament, muscle, bone, and gastrointestinal repair. Interest outside the lab centers on slow-healing soft-tissue injuries, which is where the animal endpoints are strongest.
How long does BPC-157 take to work?
The animal studies report tissue changes over days to weeks depending on the model and endpoint. No human trial has established a timeline for a subcutaneous course, so any specific week-by-week schedule you find online is extrapolated rather than measured.
Is BPC-157 safe?
The three-day intravenous pilot in two adults found no change in liver or kidney markers, and that is the full extent of the published human safety record. Two people over three days cannot characterize safety for a longer course, which is why prescriber review matters more here than it would for a well-studied drug.
Is BPC-157 legal?
It is not an FDA-approved drug, and FDA placed it in Category 2 of its bulk drug substances review. In July 2026, FDA's compounding advisory committee voted favorably on both forms, 8 to 6 with 1 abstention, though FDA has not issued a final determination. Legal status also differs from anti-doping status. The full picture is in Is BPC-157 Legal?.
Can you take BPC-157 orally?
Oral versions are marketed, but the tendon and ligament research used injected delivery in animals, and the single human pilot used intravenous infusion. An oral product carries its own absorption question and needs evidence of its own.
Does BPC-157 help with gut problems?
The gut lane is where the molecule originated and where the rodent protective findings are most developed. Human digestive conditions such as inflammatory bowel disease have treatments with human trial evidence, and those should be the starting conversation with a gastroenterologist.
How does BPC-157 compare with TB-500?
BPC-157 has direct animal tendon and ligament endpoints. TB-500 is a distinct seven-amino-acid actin-related fragment with a narrower and weaker research base. For a tendon or ligament question, BPC-157 is the better-evidenced comparison.
Bottom line
BPC-157 earns its reputation from the quality of its animal tissue studies, not from marketing. Rat tendon and ligament models measured failure load, collagen, and vascularity directly, and the mechanism work explains those results. The human trial that would turn a strong preclinical case into a clinical one has not been run yet, and that gap is the whole story of where this peptide currently stands.
Keep reading
- Peptides for Tendon Recovery
- Peptides for Achilles Tendon Recovery
- BPC-157 Injection Label Guide
- Is BPC-157 Legal? The Compounding Path and the Research-Chemical Gray Zone